MigraineMind research summary

Atogepant for the preventive treatment of high-frequency episodic migraine: Subgroup analysis from the ADVANCE and ELEVATE trials.

Headache | 2026

Clinical trial
AuthorsAshina H, Carr K, Lee MJ, Nagy K, Wang YF
JournalHeadache
Publication year2026
PubMed ID43036972

Summary

Atogepant is a new oral medication for preventing high-frequency episodic migraines. High-frequency episodic migraine (HFEM) causes increased pain and difficulties in daily life. This research looked at how effective and safe atogepant is for people with HFEM. The study included adults who had not responded well to other migraine treatments. It analyzed data from two major trials that tested atogepant over 12 weeks. Participants in one group had 8 to 14 migraine days each month. The results showed that atogepant significantly reduced the number of migraine days for these patients. It was well tolerated, meaning most people did not experience serious side effects. This analysis highlights atogepant's potential as a valuable option for patients struggling with frequent migraines. Overall, atogepant could help many individuals manage their migraines more effectively and improve their quality of life. Clinical relevance: This research indicates that atogepant may offer effective migraine prevention for patients with high-frequency episodic migraines who have not responded to other treatments.

Related migraine research topics

Original research

Read the original publication and review its full methods and findings on PubMed.

MigraineMind is an educational resource designed to complement—not replace—the original scientific literature or clinical judgement. This page is an AI-generated summary of the available paper information and may contain errors. Please consult the original publication.